UCB Pharma & LTS Lohmann v. Actavis & Mylan — Federal Circuit Rotigotine Patent Appeal
UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG brought this Federal Circuit appeal against Actavis and Mylan Technologies over US10130589B2, a patent covering polyvinylpyrrolidone stabilisation of non-crystalline rotigotine in transdermal drug delivery. The appeal ran for 706 days before closing in April 2023.
Rotigotine patent dispute reaches Federal Circuit — 706 days, no merits resolution
UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG, as plaintiffs-appellants, brought Case No. 21-1924 before the United States Court of Appeals for the Federal Circuit on 6 May 2021. The appeal concerned US10130589B2 (application number US15/884587), a patent directed to the use of polyvinylpyrrolidone for stabilising a solid dispersion of the non-crystalline form of rotigotine — the active ingredient in transdermal Parkinson's and restless legs syndrome patches. The defendants-appellees were Actavis and Mylan Technologies, Inc.
The recorded basis of termination for this case is 'Appeal Dismissed'. The docket order, however, states: 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED'. These two characterisations differ in material respects — the basis of termination records a procedural dismissal, while the verdict text records an affirmance on the merits. The specific terms and procedural history underlying this discrepancy are not disclosed in the available record.
The case closed on 12 April 2023 after 706 days of appellate proceedings. What ultimately drove the resolution — whether substantive briefing, procedural developments, or party agreement — is not determinable from the available public record. The precise scope of the appellate disposition and its downstream effect on US10130589B2's enforceability against Actavis and Mylan remain unclear from the data available.
See Complete Case & Patent Analysis →Filing to Appeal Dismissed in 706 days
706 days from filing to close — a duration consistent with Federal Circuit pharmaceutical patent appeals
US10130589B2 — Polyvinylpyrrolidone stabilisation of non-crystalline rotigotine
Any organisation developing transdermal drug delivery systems that incorporate rotigotine in its amorphous or non-crystalline form should treat US10130589B2 as a priority FTO target. This is especially relevant for generic pharmaceutical manufacturers filing ANDAs for rotigotine patches, contract development and manufacturing organisations (CDMOs) formulating solid dispersions, and patch technology developers using PVP as an excipient or stabiliser in CNS drug delivery systems.
Official order — verbatim text
The docket order records 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED', while the recorded basis of termination is 'Appeal Dismissed'. These two characterisations differ: an affirmance indicates the Federal Circuit found no reversible error in the decision below, while a dismissal typically ends proceedings on procedural grounds. The specific basis reconciling these two records is not disclosed in the available case data.
Appeal dismissed: what the recorded termination means for both parties
Procedural dismissal at appellate level — no confirmed merits ruling
The recorded basis of termination is 'Appeal Dismissed', indicating the Federal Circuit ended the case without a merits adjudication in the traditional sense. However, the docket order simultaneously states 'AFFIRMED'. These two characterisations co-exist in the record without further explanation. No settlement terms, licensing agreement, or procedural basis for dismissal are disclosed in the available data.
Appeal Dismissed (recorded)Ambiguous appellate outcome for UCB Pharma and LTS Lohmann
For UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG, the recorded basis of termination is 'Appeal Dismissed', which would typically offer no appellate vindication. The coexisting 'AFFIRMED' order, if operative, would suggest the lower decision was upheld. The specific implications for US10130589B2's enforceability against Actavis and Mylan are not determinable from the available public record.
Outcome uncertain from recordActavis and Mylan: exposure under US10130589B2 remains unclear
For Actavis and Mylan Technologies, the coexistence of a recorded dismissal and an 'AFFIRMED' docket order means the downstream patent risk from US10130589B2 cannot be cleanly assessed from the public record alone. Whether the dismissal resolves the appellate challenge definitively or leaves room for further proceedings is not stated in the available data.
Risk not determinable from recordRotigotine formulation IP: sector uncertainty persists
For generic pharmaceutical manufacturers and formulators working in transdermal rotigotine delivery, the uncertain appellate disposition of US10130589B2 — covering polyvinylpyrrolidone stabilisation of non-crystalline rotigotine — suggests continued caution is warranted. An FTO analysis against this patent and related portfolio assets remains prudent for any party developing competing solid dispersions in this space.
Transdermal pharma IP riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | UCB Pharma, Gmbh | Company | /Search in Eureka ↗ |
| Co-Plaintiff | LTS Lohmann Therapie-Systeme, AG | Company | Search in Eureka ↗ |
| Co-Plaintiff | UCB Pharma, Gmbh | Company | Search in Eureka ↗ |
| Defendant | Actavis | Individual | /Search in Eureka ↗ |
| Co-Defendant | Mylan Technologies, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Alexa Hansen | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Anthony D. Raucci Esq. | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Brian Gerard Bieluch | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Catherine McCord | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Derek J. Fahnestock | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | George Frank Pappas | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | James Trainor | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Kevin McGann | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Michael E. Bowlus | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Richard L. Rainey | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff counsel | Silvia Medina | Attorney | Counsel for UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff law firm | Covington & Burling LLP | Law Firm | Representing UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff law firm | Fenwick & West LLP | Law Firm | Representing UCB Pharma, GmbhSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing UCB Pharma, GmbhSearch in Eureka ↗ |
| Defendant counsel | Christopher T. Jagoe | Attorney | Counsel for ActavisSearch in Eureka ↗ |
| Defendant counsel | John C. O | Attorney | Counsel for ActavisSearch in Eureka ↗ |
| Defendant counsel | Thomas Fleming | Attorney | Counsel for ActavisSearch in Eureka ↗ |
| Defendant counsel | William H. Burgess | Attorney | Counsel for ActavisSearch in Eureka ↗ |
| Defendant law firm | Kirkland & Ellis, LLP | Law Firm | Representing ActavisSearch in Eureka ↗ |
| Presiding judge | Judge Kent A Jordan | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the transdermal rotigotine formulation IP space
Forward-looking patent and R&D intelligence for teams working in amorphous pharmaceutical solid dispersions, transdermal CNS drug delivery, and PVP-based stabilisation technology.
UCB Pharma and LTS Lohmann's rotigotine patent filing activity
UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG have co-developed and co-asserted patents in the rotigotine transdermal space across multiple jurisdictions. Mapping their joint and individual filing activity can reveal continuation strategies, expiry cliffs, and potential white space around rotigotine formulation improvements. Teams entering this space should profile both entities' portfolios for claim scope and filing cadence.
UCB + LTS Lohmann portfolioFiling trends in amorphous pharmaceutical solid dispersions for transdermal delivery
Patent filing activity around amorphous solid dispersions — particularly those using polymer matrices such as PVP to stabilise non-crystalline active ingredients — has been active across CNS and neurological drug delivery. Understanding the density of filings in this space helps R&D teams identify crowded claim territories and areas where novel stabilisation approaches may offer FTO advantages.
Amorphous solid dispersion trendsActavis and Mylan's patent position in transdermal CNS formulations
As defendants in this Federal Circuit appeal, Actavis and Mylan Technologies are active in the generic transdermal pharmaceutical market. Analysing their own patent filings and ANDA history in the CNS patch space can reveal their design-around strategies, proprietary formulation approaches, and potential IP assets that could affect competitive dynamics in the rotigotine market.
Generic pharma IP strategyAdjacent R&D opportunities beyond PVP stabilisation of rotigotine
US10130589B2 focuses on PVP as the stabiliser for non-crystalline rotigotine. Adjacent white space may exist around alternative polymer stabilisers, co-amorphous formulations, novel patch matrix architectures, or extended-release solid dispersion designs that fall outside the patent's claim scope. These areas may present differentiated IP filing opportunities for formulators seeking to enter the rotigotine delivery market.
Rotigotine formulation white spaceSimilar Federal Circuit pharmaceutical patent appeals: rotigotine and transdermal IP
Explore related Federal Circuit appeals involving transdermal drug delivery patents, HATCH-WAXMAN disputes, and amorphous pharmaceutical formulation IP in the same domain.
What this case signals for the transdermal pharmaceutical IP landscape
A 706-day Federal Circuit appeal over rotigotine formulation IP highlights the enforcement complexity in HATCH-WAXMAN-adjacent transdermal drug delivery disputes.
Rotigotine formulation patents remain a live enforcement risk for generic manufacturers
US10130589B2 covers a specific polyvinylpyrrolidone stabilisation mechanism for non-crystalline rotigotine. Any generic or biosimilar developer targeting rotigotine transdermal delivery should conduct a thorough FTO review against this patent and related UCB Pharma and LTS Lohmann portfolio assets before advancing to commercialisation.
Divergent termination records at the Federal Circuit warrant careful docket monitoring
This case demonstrates that 'Appeal Dismissed' and 'AFFIRMED' can appear simultaneously in a Federal Circuit docket record. IP professionals tracking enforcement exposure should verify the operative order — not just the database termination label — before drawing conclusions about a patent's appellate status.
UCB v Actavis — key questions answered
Case No. 21-1924 is a Federal Circuit appeal filed on 6 May 2021 by UCB Pharma GmbH and LTS Lohmann Therapie-Systeme AG against Actavis and Mylan Technologies, Inc. The dispute concerns US10130589B2, a patent covering polyvinylpyrrolidone stabilisation of non-crystalline rotigotine for transdermal delivery. The case closed on 12 April 2023 after 706 days.
US10130589B2 (application US15/884587) protects the use of polyvinylpyrrolidone to stabilise a solid dispersion of non-crystalline rotigotine — the active ingredient in transdermal patches for Parkinson's disease and restless legs syndrome. Keeping rotigotine in its amorphous form is essential for patch efficacy, making this stabilisation patent a key barrier to generic entry in the rotigotine transdermal market.
The recorded basis of termination is 'Appeal Dismissed'. However, the docket order states 'THIS CAUSE having been considered, it is ORDERED AND ADJUDGED: AFFIRMED'. These two characterisations differ. The specific procedural basis reconciling them is not disclosed in the available public record. Both are reported here as-is; the reader should consult the operative docket order directly.
Plaintiff counsel included attorneys from Covington & Burling LLP, Fenwick & West LLP, and Morris, Nichols, Arsht & Tunnell LLP. Named attorneys included George Frank Pappas, Jack B. Blumenfeld, Richard L. Rainey, and others. Defendants Actavis and Mylan were represented by Kirkland & Ellis, LLP, with attorneys including William H. Burgess, Thomas Fleming, and Christopher T. Jagoe.
Yes. Any company developing rotigotine transdermal formulations — particularly those using polymeric stabilisers such as PVP to maintain amorphous rotigotine in a solid dispersion — should conduct an FTO analysis against US10130589B2 and the broader UCB Pharma and LTS Lohmann patent family. The patent's claim scope and the unresolved appellate record make it a priority risk asset for generic and CDMO entrants in this space.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.